



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 16/00, C12N 5/00, G01N 33/53, A61K 39/395	A1	(11) International Publication Number: WO 96/29348 (43) International Publication Date: 26 September 1996 (26.09.96)
(21) International Application Number: PCT/US96/03965 (22) International Filing Date: 22 March 1996 (22.03.96) (30) Priority Data: 08/409,851 23 March 1995 (23.03.95) US (71) Applicant: INDIANA UNIVERSITY FOUNDATION [US/US]; Showalter House, Box 500, Bloomington, IN 47402 (US). (72) Inventors: KWON, Byoung, S.; Indiana University of Medicine, Medical Science, Room 255, 635 Barnhill Drive, Indianapolis, IN 46223 (US). KANG, Chang-Yuil; SNU Faculty, Apartment No. 302, 244-2, Bong Chun - 7th Dong, Kwanak-gu, Seoul 151-742 (KR). (74) Agent: MICHAELS, Christopher, A.; Barnard, Brown & Michaels, Suite 220, 306 E. State Street, Ithaca, NY 14850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: MONOCLONAL ANTIBODY AGAINST HUMAN RECEPTOR PROTEIN 4-1BB AND METHODS OF ITS USE FOR TREATMENT OF DISEASES (57) Abstract Disclosed herein is a monoclonal antibody against H4-1BB that can be used to enhance or suppress T-cell activation and proliferation by treating T-cells that have expressed receptor protein H4-1BB with the anti H4-1BB monoclonal antibody. Also disclosed herein is cDNA for the human receptor H4-1BB. The cDNA of the human receptor H4-1BB is about 65 % homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from murine cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein (alkaline phosphatase) bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation or against autoimmune diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**MONOCLONAL ANTIBODY AGAINST HUMAN RECEPTOR PROTEIN 4-1BB
AND METHODS OF ITS USE FOR TREATMENT OF DISEASES.**

5

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of co-pending application Serial No. 08/122,796 filed September 16, 1993, which is a continuation-in-part of co-pending application Serial No. 08/012,269 filed February 1, 1993, which is a continuation-in-part
10 of co-pending application Serial No. 07/922,996 filed July 30, 1992, which is a continuation-in-part of copending application Serial No. 07/267,577 filed November 7, 1988, now abandoned.

The subject matter described herein was in part a subject invention of NIH Grants Nos. IR23AI23058-03, RO1 AI28175 and P60 KD20542 of which the present inventor was the
15 Principal Investigator and either the Donald Guthrie Foundation for Medical Research Inc. of Guthrie Square, Sayre, Pennsylvania 18849-1669 or Indiana University School of Medicine of Indianapolis, Indiana 46202, was the Grantee.

FIELD OF THE PRESENT INVENTION

20 The present invention relates to a previously unknown human receptor protein, H4-1BB, a monoclonal antibody that specifically recognizes H4-1BB and a ligand protein to H4-1BB. H4-1BB was isolated and identified by research on a homologous murine (mouse) receptor protein, 4-1BB, which was isolated and identified by specific expression of the T cell genes by the present inventor.

25

BACKGROUND OF THE PRESENT INVENTION

The immune system of humans and other species require that white blood cells, which include phagocytes, T lymphocytes and B cells, be made in the bone marrow. As presently understood, the phagocytes include macrophage cells which scavenge unwanted materials such as virus proteins from the system. The lymphocytes include helper T cells and killer T cells and B cells as well as other cells, including those categorized as suppressor T cells. The B cells produce the antibodies. The killer T cells physically pierce the cell and the helper T cells facilitate the whole process. The immune process is facilitated by lymphokines.

Lymphokines are the proteins by which the immune cells communicate with each other. Scientists produce them in sufficient quantities for therapeutic use against immunologic diseases. There are many known lymphokine proteins and they include the interferons, interleukin-1,2,3,4,5,6,7, colony-stimulating factors, lymphotoxin, tumor necrosis factor and erythropoietin, as well as others.

Interleukin 1, secreted from macrophages activate the helper T cells and raise the body temperature causing fever which enhances the activity of the immune cells. The activated helper T Cells produce Interleukin 2, which in turn stimulates the helper and killer T cells to grow and divide. The helper T cells also produce another lymphokine, B cell growth factor (BCGF), which causes B cells to multiply. As the number of B cells increases, the helper T cells produce another lymphokine known as the B cell differentiating factor (BCDF), which instructs some of the B cells to stop replicating and start producing antibodies. T cells also produce a lymphokine, gamma interferon (IF), which has multiple effects like Interleukin 2. Interferon helps activate killer T cells, enabling them to attack the invading organisms. Like BCGF, interferon increases the ability of the B cells to produce antibodies. Interferon also keeps the macrophages at the site of the infection and helps the macrophages digest the cells they have engulfed. Gathering momentum with each kind of lymphokine signal between the macrophages and the T cells, the lymphokines amplify the immune system response and the virus protein or other foreign matter on the infected cells is overwhelmed. There are many other lymphokines, maybe a hundred or more, which participate in the immune process. Many lymphokines are known and many are not.

Lymphokine activities are produced when a certain lymphokine binds to its specific receptor. Among scientists there is widespread use of cloned cell lines for production of lymphokines and their receptors. The isolation of lymphokine and lymphokine receptor mRNA has become a common technique. The mouse receptor protein, 4-1BB, was isolated
5 and identified based on specific expression of the T cell genes using a technique identified by the present inventor in a publication (Proc. Natl. Acad. Sci. USA. 84, 2896-2900, May 1987, Immunology). The protocol reported in this publication can be used by scientists to detect virtually all of the lymphokines. The method is designed to detect virtually all mRNA expressed differentially and the mRNA sequences of the immune cells are expressed
10 differentially (as they relate to the T cells and the killer T cells) even though the level of expression is low and the quantity of the lymphokine and its receptor protein is low. The present inventor believes that the analysis described in the above identified publication can reveal biologically important molecules such as lymphokines and their receptors because there are many indications that biologically important or active molecules are coded by the most
15 scarce messages.

Most T cell factors have been classically identified by recognizing biologic activities in assays, purifying the protein information. An alternative approach is to isolate putative T cell genes based upon specific expression and then demonstrate the function of the unknown molecule. Using the aforesaid modified differential screening procedure, the present inventor
20 cloned a series of T cell subset-specific cDNAs from cloned helper T (HTL) L2 and cloned cytolytic T lymphocyte (CTL) L3.

T cells are critically important in acquired immunity, providing protection against viral, bacterial and parasitic infection. T cells are activated when they encounter peptide from the invading pathogen in context with self-MHC via the T cell's own T cell receptor
25 (TCR) complex and other costimulatory molecule(s), such as CD28(1,2). Without the engagement of the other co-stimulatory molecule(s) the T cell is rendered anergic(3). To date the best characterized co-stimulatory molecule has been CD28(1,2). More recently, however, other cell surface molecules have been suggested to play a co-stimulatory role, such as the molecule 4-1 BB. 4-1 BB is a -55 kDa homodimeric molecule expressed on
30 activated T cells in the mouse and is a member of the Nerve Growth Factor receptor

(NGFR)/Tumor Necrosis Factor receptor (TNFR) gene family(4). This family is characterized by the presence of cysteine-rich motifs in the extracellular domains. Other members of this family include NGFR, B cell activation molecule CD40, the T cell activation molecule OX-40 in rat and CD27, the two receptors for TNF called TNFR-1
5 and TNFR-11, the apoptotic inducing molecule called Fas, and CD30 which has been suggested to play a role in the regulation of cellular growth and transformation(4,5).

A series of T-cell subset-specific cDNAs were isolated from cloned murine T-cells by employing a modified differential screening procedure. The nucleotide sequence and expression properties of some of the cDNA species have been reported. One of the genes not
10 previously characterized, that encodes mouse receptor protein 4-1BB, was studied further. These studies have led to the isolation of the human homologue to 4-1BB, H4-1BB.

Specific immune responses are governed by the recognition of antibodies to foreign antigens. Antibodies form a family of structurally related glyco-proteins and confer the protective effect of cell-mediated immunity. Antibodies are produced by B lymphocytes and
15 are bound to the cell membrane, functioning as B cell receptors for antigens. Antibodies are also secreted by B cell progeny which differentiate in response to stimulation by antigens. A specific antigen will trigger the complementary B lymphocyte to proliferate and differentiate into effector cells which then eliminate the antigen. Each lymphocyte produces an antibody of a particular specificity, and thus immune responses are very specific for distinct antigens. The
20 portion of the antigen recognized by T and B lymphocytes are called epitopes or determinants.

The development of techniques to produce virtually unlimited amounts of a single (monoclonal) antibody for a specific antigenic epitope has had an enormous impact on clinical immunology. To produce a monoclonal antibody of known specificity, a mouse can be injected with a particular antigen, such as a receptor protein and the spleen B lymphocytes (that
25 produce the antibody against the protein) can be fused via somatic cell hybridization to a myeloma (lymphocyte tumor) to produce an immortal cell line. This is done because normal B lymphocytes can not grow indefinitely, yet when fused with the myeloma, the resulting hybridoma does produce a virtually endless supply of a specific monoclonal antibody.

"Selection" mediums have been developed to ensure that only the fused cells continue to grow.
30 Each hybridoma cell is specific for only one antigenic determinant. If several hybridomas are

produced that secrete antibodies that recognize and bind to the surface of a particular cell, each hybridoma clone will secrete an antibody for only one surface antigenic determinant. To determine which mAbs specifically bind to the protein receptor, the hybridomas can be screened with ELISA (enzyme-linked immunosorbent assay).

- 5 Monoclonal antibodies have numerous applications: 1) The hybridoma can produce large quantities of specific antibodies that are normally either unavailable in small quantities or not available at all; 2) the hybridoma can be directed to produce antibodies against a single antigen determinant which, for complex antigens, may be normally very difficult; 3) pure antibodies can be obtained against antigens that cannot be purified; 4) immunodiagnosis of
- 10 infectious and systemic diseases by detecting specific antigens circulating in tissues or using monoclonal antibodies in immunoassays; 5) characterization of protein receptors and the role they play in the transition from a naive to a memory T cell; and 6) blocking or enhancing immune response.

15

SUMMARY OF THE PRESENT INVENTION

The present invention includes the human receptor protein H4-1BB and the cDNA gene encoding for human receptor protein H4-1BB. The nucleotide sequence of the isolated cDNA is disclosed herein along with the deduced amino acid sequence. The cDNA gene identified as pH4-1BB was deposited at the Agricultural Research Service Culture Collection and assigned

20 the accession number: NRRL B21131

The cDNA, including its fragments and derivatives, can be used as a probe to isolate DNA sequences encoding for proteins similar to the receptor protein encoded by the cDNA. The cDNA of the human receptor, H4-1BB, is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from cDNA 4-1BB. The cDNA gene identified

25 as p4-1BB was deposited at the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC No.: 67825.

The human receptor protein H4-1BB can be produced by: 1) inserting the cDNA of H4-1BB into an appropriate expression vector, 2) transfecting the expression vector into an

appropriate transfection host, c) growing the transfected hosts in appropriate culture media and d) purifying the receptor protein from the culture media. The protein and fragments and derivatives can be used: 1) as a probe to isolate ligands to human receptor protein H4-1BB, 2) to stimulate proliferation of B-cells expressing H4-1BB ligands, or 3) to block H4-1BB ligand binding.

B-cell proliferation can be induced by treating B-cells that have expressed a ligand to receptor protein H4-1BB with cells that have expressed receptor protein H4-1BB. The use of H4-1BB protein, H4-1BB ligand protein, or fragments of the proteins, to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation. A similar costimulatory immune system pathway is being analyzed for this type of application. See "Mounting a Targeted Strike on Unwanted Immune Responses", Jon Cohen, Science, Vol. 257, 8-7-92; "Long Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig", Lenschow et al, Science Vol. 257, 7-8-92; and "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule", Linsley et al, Science Vol. 257 7-8-92.

A monoclonal antibody against H4-1BB can be used to enhance T-cell proliferation by treating T-cells that have expressed receptor protein H4-1BB with the anti H4-1BB monoclonal antibody. Some tumors are potentially immunogenic but do not stimulate an effective anti-immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the co-stimulatory signals necessary for full activation of T cells. Expression of the co-stimulatory ligand B7 on of melanoma cells was found to induce the rejection of a murine melanoma in vivo. ("Tumor Rejection After Direct Co-Stimulation of CD8⁺ T Cells by B7-Transfected Melanoma Cells", Sarah E. Townsend and James P. Allison, Science Vol. 259, 1-5-93.) A monoclonal antibody against H4-1BB may be capable of the same effect as it is now known to induce T cell proliferation and activation.

The present invention includes a monoclonal antibody 4B4-1 that specifically recognizes an epitope on the extracellular domain of human receptor protein 4-1BB on peripheral blood T cells. The monoclonal antibody is produced from a hybridoma identified as 4B4-1 and deposited under the Budapest Treaty at the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC No.: HB-11860.

The 4B4-1 mAb will have great utility in assessing the role of the 4-1BB receptor protein in the transition from naive to memory T-cells. In addition, by treating T-cells that have expressed receptor protein 4-1BB with 4B4-1 mAb T-cell proliferation and activation can be enhanced. Cross-linking of the 4-1BB with 4B4-1 mAb will produce the effects similar to
5 the binding of the 4-1BB ligand to 4-1BB. The cross-linking effect makes the 4B4-1 mAb very useful for culturing T-cells because cross-linking is necessary for adequate proliferation. Therefore, the 4B4-1 mAb is a useful adjunct to T-cell culture medium. The mAb can also be used to enhance T-cell activation which is useful in the treatment of cancers that avoid normal immune responses.

10 A mAb against H4-1BB can also be used to interfere with H4-1BB and H4-1BB ligand binding. By interfering with the ligand binding, the immune responses will be suppressed. The mAb is useful as a tool to elucidate the mechanisms of auto-immune disease and can be used to control such problems. For example, the mAb described herein can be used to rheumatoid arthritis, systemic lupus erythematosus, and diabetes. The blocking effect can also
15 be used to suppress the immune system during organ transplantation.

The monoclonal antibody against the murine 4-1BB ligand was produced by injecting Sprague-Dawley rats with purified recombinant protein of the 4-1BB ligand. The spleen cells were then fused to myeloma cell line SP/O. The positive clones were tested with H4-1BB expressing T-cell line. Each step of these processes summarized here will be described in
20 detail below.

The monoclonal antibody can be used enhance T-cell proliferation and activation. This can be done by treating T-cells that have expressed receptor protein 4-1BB with anti H41-BB monoclonal antibody.

A fusion protein can detect cell membrane ligands to human receptor protein, H4-1BB.
25 A fusion protein of the present invention comprises the extracellular portion of the receptor protein H4-1BB and a detection protein (alkaline phosphatase) bound to the portion of the receptor protein H4-1BB. The portion of the receptor protein H4-1BB binds to the cell membrane ligands and binding can be detected by relative activity assays for the detection protein. The fusion protein is placed in the presence of a cell suspected to express the receptor

protein H4-1BB. Then the cell is washed of any fusion protein not bound to the cell membrane ligands. Once the washed cells are placed in the presence of a substrate for the detection protein and the relative activity of the detection protein can be measured.

The primary object of the present invention is the identification of the new human
5 receptor, H4-1BB as identified herein by its sequence.

Another object of the present invention is to teach a fusion protein comprising the extracellular portion of H4-1BB and a detection protein.

Still another object of the present invention is to teach methods of using the cDNA H4-1BB, the receptor protein H4-1BB, the monoclonal antibody and the ligand for H4-1BB.

10

BRIEF DESCRIPTIONS OF THE FIGURES

Figures 1a and 2b illustrate the molecules involved in T-cell activation.

Figures 2a, 2b, and 2c illustrate a normal T-cell activation pathway.

Figures 3a, 3b, and 3c illustrate CTLA4-Ig alone, 4-1BB/AP and CTLA4-Ig together
15 and 4-1BB/AP alone respectively being used to block steps in the T-cell activation pathway.

DETAILED DESCRIPTION

In the following detailed description references are made to known procedures and studies, as well as published work of the applicant. These publications are incorporated herein
20 by reference for clarity and listed in an Appendix A at the end of this detailed description. A list of common abbreviations is included in Appendix B.

The following description teaches the isolation of 4-1BB and its human homologue, H4-1BB, the preparation of the peripheral blood cells, including the antibodies and reagents used, the production of fusion protein, immunization and monoclonal antibody
25 production, and immunoprecipitation studies. In short, the research shows that the

monoclonal antibody 4B4-1 specifically binds to human receptor protein 4-1BB on peripheral blood T cells. The results are coupled with the precise detail of the methods employed.

5 Isolation and characterization of mouse receptor 4-1BB

SEQ ID NO:1 shows the nucleotide sequence and the deduced amino acid sequence of the mouse receptor 4-1BB. The predicted amino acid sequence is shown below the nucleotide sequence. The transcript of 4-1BB was inducible by concanavalin A in mouse splenocytes, T cell clones, and hybridomas. The expression of 4-1BB transcripts was inhibited by cyclosporin

- 10 A. The 4-1BB mRNA was inducible by antigen receptor stimulation but was not inducible by IL-2 stimulation in the cloned T-cells (1). The 4-1BB cDNA encodes a peptide of 256 amino acids containing a putative leader sequence, a potential membrane anchor segment, and other features of known receptor proteins. Therefore, the expression pattern of 4-1BB resembles those of lymphokine mRNAs while the sequence appeared consistent with those of receptor
15 proteins.

- The major species of 4-1BB on the cell surface appears to be a 55-kDa dimer. 4-1BB also appears to exist as a 30-kDa monomer and possibly as a 110-kDa tetramer. Since these 4-1BB species were immunoprecipitated from a homogeneous population of cells (T-cell clone f1), all forms potentially co-exist on each cell. We will need to compare the peptide digests
20 from the 4-1BB monomer and dimer to determine whether 4-1BB exists as a homodimer on the cell surface. A variety of cell surface receptors such as the insulin receptor(2), the B cell surface immunoglobulin receptor (3), the T cell Ag receptor (4), the CD28 costimulatory receptor (5), and the CD27 T-cell antigen (6) are composed of disulfide-bonded subunits. Receptor dimerization may be required for ligand binding and subsequent biochemical
25 signalling.

4-1BB is not expressed on resting T cells but is inducible by activators which deliver a complete growth stimulus to the T cell. The combination of PMA and ionomycin is capable of mimicking those signals required for T cell proliferation. Although PMA or ionomycin alone induced 4-1BB mRNA, the combination of PMA and ionomycin resulted in optimal 4-1BB

expression. Furthermore, the expression of 4-1BB was not transient. When purified splenic T-cells were stimulated with immobilized anti-CD3, 4-1BB mRNA was expressed and this expression was maintained for up to 96 hrs poststimulation. Cell cycle analysis will be required to confirm that 4-1BB is expressed throughout cell cycle progression.

- 5 4-1BB is structurally related to members of the nerve growth factor receptor super-family. Although these receptors possess structurally similar ligand-binding properties (cysteine-rich regions), the cytoplasmic domains of these proteins are nonconserved which could allow for diversity in transmembrane signaling. Some members of this family are involved in the T or B cell activation process. There are in vitro functional data on the OX-40,
10 CD40 and CD27 antigens. Antibodies against the OX-40 augment the T-cell response in a mixed lymphocyte reaction (7) and antibodies against CD40 enhance B-cell proliferation in the presence of a coactivator, such as PMA or CD20 antibodies, and synergize with IL-4 in vitro to induce B-cell differentiation and to generate long-term normal B cell lines (8). One monoclonal antibody, anti-1A4, which recognizes an epitope on the CD27 molecule inhibited
15 calcium mobilization, IL-2 secretion, helper T cell function, and T-cell proliferation. On the other hand, CLB-CD27/1, another anti-CD27 mAb enhanced proliferation of human T cells stimulated with PHA or anti-CD3 mAb (6). These results indicate that the CD27 molecule plays an important role in T cell activation. Except for TNFRs, NCFR and CD40, the ligands or cell surface molecules to which the members of the superfamily bind are not yet identified.
20 Identification and characterization of the ligands to which the receptors bind will be helpful in better defining the physiologic role of 4-1BB.

To ascertain whether cell surface 4-1BB could contribute to T cell activation, the anti-4-1BB 53A2 was used as an antagonist to 4-1BB. These data suggested that 4-1BB does in fact have the potential to function as an accessory signaling molecule during T cell activation
25 and proliferation. The addition of soluble 53A2 to purified splenic T cells stimulated with immobilized anti-CD3 resulted in an amplification of ³H thymidine incorporation compared to T cells stimulated with anti-CD3 alone. This pattern of enhancement ranged from 2- to 10-fold in three independent experiments.

In the original two signal model of Bretcher and Cohn, they proposed that signal 1, the
30 occupancy of the T cell antigen receptor (TCR), resulted in inactivation of the T cell in the

absence of signal 2, which is provided by accessory cells. This has since been confirmed by a variety of studies (9). The identification of the accessory cell CD28 as a potent costimulatory receptor on T cells was a significant contribution in beginning to characterize the accessory signal(s) required for optimal T cell proliferation (10). It is possible that other cell surface
5 molecules may contribute to these costimulatory activation requirements (11).

The biochemical signals delivered through 4-1BB are not completely known. One possibility considered was the observation that 4-1BB contains a putative p56^{lck} tyrosine kinase binding domain in its cytoplasmic tail. It was later determined that p56^{lck} tyrosinase kinase binds to 4-1BB. It will also be worthwhile to determine if 4-1BB-mediated signaling can
10 regulate genes such as IL-2 and IL-2 receptor, whose expression is required for T cell activation and subsequent proliferation.

The precise functions of members of the Nerve Growth Factor Receptor (NGFR) family appear to be diverse. An emerging theme of inquiry concerns the ability of these molecules to maintain the responsiveness or viability of the particular cell type in which they
15 are expressed. For instance, NGF is absolutely required for viability of neurons *in vitro* and *in vivo* (12). The crosslinking of CD40 by soluble antiCD40 monoclonal antibody blocks germinal center centrocytes from undergoing apoptosis *in vitro* (13). Signals delivered through CD40 may also aid in maintenance of responsiveness to differentiation factors. The ligation of CD40 with anti-CD40 F(ab')₂ fragments in the presence of IL-4 induced large increases IgE
20 synthesis (14). Also, anti-CD40 activated naive B cells treated with IL-10 and transforming growth factor- β became committed to IgA secretion (15). In addition to sharing the molecular characteristics with the NGFR superfamily, it was noted that the 4-1BB contained a putative zinc finger structure of the yeast eIF-2b protein (16). 4-1BB also shares a conserved region with the *sina* *seven in absentia* of *Drosophila*, which is required for correct photoreceptor cell
25 development (17). That particular region is also similar to the protein product of the DGI7 gene of *Dictyostelium*, whose expression is specifically induced during aggregation by cAMP (18).

This region forms the pattern of C-X₂-C-X₉-C-X₃-H-X₃-C-X-C; and the cysteines and histidine are conserved in a similar space in 4-1BB, *sina*, and DGI7 proteins. Ten of 24 amino acids between the 4-1BB and *sina* proteins are identical; 3 of 24 are conservative substitutes.
30 The conserved pattern suggests that these amino acids are functionally important. The *sina*

protein is localized in the nucleus, suggesting that it has a regulatory function in cells. The fact that the amino acid sequence of 4-1BB contains features like a zinc finger motif, a nuclear protein, and a receptor domain suggests that 4-1BB may play diverse roles during cellular proliferation and differentiation.

5 In addition, 4-1BB may represent another cell-surface molecule involved in T cell-APC interactions. The 4-1BB-AP fusion protein specifically bound to mature B-cell lines, anti- μ -activated primary B cells, and mature macrophage-cell lines. 4-1BB-AP bound at low or insignificant levels to immature B- and macrophage-cell lines, T cell clones, T cell lines, primary culture T cells, and various nonlymphoid-cell lines. Since 4-1BB-AP binds to mature
10 B cells and macrophages, it is possible that signals delivered upon 4-1BB binding may modulate APC functions in some way. This possibility remains to be explored.

Chalupny and colleagues (19) have proposed that 4-1BB Rg, a fusion protein consisting of the extracellular domain of 4-1BB and the Fc region of human IgG, bound to the extracellular matrix (ECM). The highest level of 4-1BB Rg binding was to human vitronectin.
15 In data not shown, an ELISA was performed using 4-1BB-AP and human vitronectin (Yelios Pharmaceuticals/GIBCO-BRL, Grand Island, NY) immobilized at 0.007 mg-10mg per well on microtiter plates. No binding of 4-1BB-AP based on AP activity was observed. To rule out the possibility that 4-1BB-AP was binding to proteins extrinsically attached to the cell surface (possible extracellular matrix components), B-cell lymphomas were washed in acid conditions
20 prior to the binding assay. 4-1BB-AP still bound specifically to mature B-cell lymphomas. It is still to be determined whether a 4-1BB-ligand specifically expressed on B cells and macrophages exists, and whether 4-1BB-AP may bind to the ECM under particular binding conditions. It is possible that the ECM could facilitate the binding of 4-1BB to a specific cell-surface ligand.

25 B cells and helper T cells interact with each other through receptors on B cells binding to their specific counter-receptors on T cells. Researchers believe that this interaction results in a cascade of biochemical signaling relays between these two cell types (20). As this interaction proceeds, these cells become committed to enter the S phase of the cell cycle. Initial interactions between TCR and CD4 on T cells, and processed antigen-MHC II on B cells, do
30 not result in B cells capable of entering the cell cycle (21). However, studies from in vitro

systems suggest that once T cells are stimulated, they express newly synthesized or modified cell-surface molecules capable of inducing B cells to enter the cell cycle (22, 23). This T cell function is not antigen-specific or MHC-restricted (24). In addition, soluble factors are not required for the activated Th induction of B-cell activation (25). Once B cells enter the cell cycle, IL-4 induces B cells to progress from G₁ to S phase. The ability of activated T cells or T-cell membranes to promote the entry of B cells into the cell cycle can be blocked by either cycloheximide or cyclosporin A treatment (26, 27). These newly expressed membrane proteins appear to be "lymphokine-like" in their induction characteristics.

4-1BB has expression properties which meet the requirements of a B-cell costimulator. 4-1BB is inducible by anti-CD3 or TCR-mediated T-cell stimulation, and its expression is sensitive to cyclosporin A as well as cycloheximide treatment (28). Interestingly, paraformaldehyde-fixed SF21-4-1BB cells, synergized anti- μ and induced B-cell proliferation. The costimulation of splenic B cells by SF21-4-1BB occurred at optimal (10 μ g/ml) and suboptimal (1.0-0.1 mg/ml) doses of anti- μ . The addition of SF21-4-1BB cells to resting B cells, did not result in significant B-cell proliferation. SF21-4-1BB cells did not synergize with TPA or ionomycin, or suboptimal concentrations of LPS in inducing B-cell proliferation.

Although the baculovirus system has been used to express large amounts of recombinant soluble proteins; this system may be utilized for the expression of recombinant cell-surface proteins. The baculovirus infection provides a convenient means to express uniformity high levels of recombinant protein on a per cell basis. It is noteworthy, that the addition of SF21 cells alone did not result in significant levels of costimulation. This can be a potential problem when using cos- or L- cell lines which can exhibit strong costimulator activity on their own.

Another member of the NGFR superfamily, CD40, is expressed on B cells and interacts with gp39, a molecule expressed on activated T cells. The cDNAs encoding the murine (29) and human (30) gp39 proteins have been cloned; this cell surface molecule is a type II membrane protein with homology to tumor necrosis factor. Noelle et al. (31) found that a CD40-immunoglobulin fusion protein, is capable of blocking T cell-induced B-cell proliferation and differentiation in a dose-dependent manner. Armitage et al. have isolated a cDNA for murine gp39 and showed that gp39 could induce B-cell proliferation in the absence

of co-stimuli, and result in IgE production in the presence of IL-4. Hollenbaugh et al. (32) have shown that COS cells transfected with human gp 39 can synergize with either TPA or anti-CD20 in inducing human B-cell proliferation and is able to stimulate B cells without a costimulator only at low levels. These data indicate that CD40 may be one of the

5 B-cell-surface molecules that transmit signals during physical contact with T cells.

Cell-surface receptors communicate with their external milieu by interacting either with soluble factors or other cell surface molecules expressed on neighboring cells. The role of biochemical signals delivered by cell-cell contact versus those delivered by soluble factors

10 interacting with cell surface receptors is not clear. The NGFR superfamily is unusual for the TNFR I and II as well as the NGFR bind to more than one ligand. The TNFRs I and II both bind to TNF- α and TNF-R (33). The NGFR binds to NGF, brain-derived neurotrophic factor, and neurotrophin-3 (34).

In addition, one ligand may function as both a cell surface and soluble ligand. Recent

15 evidence on the CD40 ligand, gp39, suggests that this ligand can exist as a membrane bound as well as a soluble ligand (35). It may be possible that 4-1BB is secreted and interacts with B cells in a soluble form as well as a membrane bound form. A member of the NGFR receptor family, CD27, which is expressed on T cells, is secreted in addition to being expressed on the cell surface (36). It is also possible that more than one 1 ligand (soluble and cell surface) may

20 bind to 4-1BB.

Isolation of the human homologue, H4-1BB

In order to isolate the human homologue (H4-1BB) of mouse 4-1BB two sets of polymerase chain reaction (PCR) primers were designed. To design the PCR primers, the

25 amino acid sequence among the members of nerve growth factor receptor (NGFR) superfamily were compared because 4-1BB is a member of the superfamily (37). The amino acid sequences employed were mouse 4-1BB (38), human NGFR (39), human tumor necrosis factor receptors (33), human CD40 (40), and human CD27 (6). The areas of sequence conservation among the NGFR superfamily were chosen.

(NOTE: WILL BE REVISED TO REFER TO SEQUENCE LISTINGS - STILL BEING PREPARED)

Forward primer I (H4-1BBFI) spans from amino acids 36 to 41 and forward primer II (H4-1BBFII) spans from amino acids 52 to 58 of the mouse 4-1BB. Reverse primer I (H4-1BBRI) spans from amino acids 116 to 121 and reverse primer II (H4-1BBRII) spans from amino acids 122 to 128 of mouse 4-1BB. The regions used as PCR primers in mouse 4-1BB are indicated in Fig. 1.

The degenerative oligonucleotide sequence of each primer are shown in the Sequence Listing as follows:

10	SEQ ID NO:3	H4-1BBFI
	SEQ ID NO:4	H4-1BBFII
	SEQ ID NO:5	H4-1BBRI
	SEQ ID NO:6	H4-1BBRII

15 Peripheral blood lymphocytes from normal healthy individuals were isolated and activated with PMA (10 ng/ml) and ionomycin (1 mM). mRNA from the lymphocytes was isolated. Using reverse transcriptase the human lymphocyte mRNA was converted to single-stranded cDNA. The cDNA was then amplified with Taq polymerase with combination of the primers. The combination of primers was as follows: H4-1BBFI vs H4-1BBRI; H4-1BBFI vs
20 H4-1BBRII; H4-1BBFII vs H4-1BBRI; and H4-1BBFII vs H4-1BBRII.

The primer set of H4-1BBFII and H4-1BBRII produced a specific band of ~240bp. The 240bp is an expected size of human 4-1BB if the human homologue protein is similar to mouse 4-1BB in size. The PCR product (240bp) was cloned in PGEM3 vector and sequenced. One open reading frame of the PCR product was ~65% identical to mouse 4-1BB. Therefore,
25 it was concluded that the 240 bp PCR product is the human homologue of mouse 4-1BB. The 240 bp PCR product was used to screen λ gt11 cDNA library of activated human T lymphocytes. An ~0.85 kb cDNA was isolated. The sequence of the cDNA is shown in SEQ ID NO:7 and the predicted amino acid sequence is shown in SEQ ID NO:8

An expression plasmid to produce H4-1BB-AP fusion protein was constructed.

The 5' portion of the H4-1BB cDNA including sequences encoding the signal sequence and the entire extracellular domain, was amplified by PCR. For correctly oriented cloning, a Hind III site on the 5' end of the forward primer and a Bgl II site on the 5' end of the reverse
5 primer were created.

The Hind III - Bgl II H4-1BB fragment was inserted into the mammalian expression vector APTaq-1, upstream of the coding sequence for human placental alkaline phosphatase (AP). The oligonucleotides PCR primers used for the amplification of 5' portion of H4-1BB are shown in the Sequence Listing as SEQ ID NO:9 for the forward
10 primer and SEQ ID NO:10 for the reverse primer.

H4-1BB-AP will be used to identify cells and tissues that express ligand for human 4-1BB (i.e. H4-1BBL). The studies with mouse 4-1BB indicated that the ligand for 4-1BB is on the cell surface. B cells and macrophages were major cells that express 4-1BBL. It is expected that H4-1BBL also expresses on human B cells and macrophages.

15 A mammalian expression cDNA library will be generated from human cell lines that express H4-1BBL. The library will be screened by [¹²⁵] I-labeled H4-1BB-AP. cDNA for H4-1BBL will then be isolated and characterized. Soluble recombinant H4-1BBL will then be produced. Both H4-1BB-AP and H4-1BBL will be used to suppress or enhance immune responses as described below. Monoclonal antibody to H4-1BBL will be produced and
20 monoclonal antibody to H4-1BB is discussed below.

According to studies with murine 4-1BB, 4-1BB acts as a costimulatory signal. It is expected that H4-1BB will act as a costimulatory signal for T cell activation. Mouse 4-1BB helped B cells with proliferation and differentiation. It is expected that H4-1BB will do the same. H4-1BB-AP, H4-1BBL and monoclonal antibody can be used to suppress or enhance
25 human immune responses.

Figures 1a and 1b illustrate the molecules involved in T-cell activation. During early T-cell activation (cognitive phase), resting T cells express the TCR/CD3 complex and other "accessory" molecules. Among these constitutively expressed molecules, CD4 (or CD8),

LFA-1 and CD28 are probably the ones to receive costimulatory signals. Initial interaction with the TCR/CD3 complex in combination with these 'accessory' costimulatory signals leads to subsequent expression of additional receptor molecules such as CD28, CTLA4, and 4-1BB. These newly expressed molecules are probably going to receive additional important
5 costimulatory signals at later stages of T-cell activation (clonal expansion).

Suppression of immune responses.

Figures 2a-c illustrate a normal T-cell activation pathway. Figures 3a-c illustrate the blocking of immune responses with soluble chimera of 4-1BB. If 4-1BB plays a role in T-cell
10 activation, blocking of the interaction to its ligand on antigen-presenting cells should result in suppression of T-cell dependent immune responses. It is well documented that blocking of the interaction of CD28 to its counter-receptor B7 suppresses in varying degrees, both in vivo antibody production and cell-mediated immune responses. Blocking of both interactions should result in a more effective immunosuppression; since 4-1BB is induced during T-cell activation.
15 Blocking of the interaction of 4-1BB to its ligand may be of importance at later stages of the activation process where the CD28/B7 interaction may no longer be of relevance.

As illustrated with mouse receptor 4-1BB and mouse ligand 4-1BBL above, addition of H4-1BB-AP will coat the H4-1BBL expressing cells and block the normal interaction between H4-1BB and H4-1BBL. This will lead to immunosuppression. This type of
20 immunosuppression is antigen-specific. Therefore it avoids the generalized immunosuppression produced by antiCD3 or cyclosporin A treatments. H4-1BB-AP treatment can be used to treat certain autoimmune diseases and to facilitate organ transplantation.

Immune enhancement.

25 H4-1BB may function at the late stage of T cell activation and may be a critical molecule for completion of T cell activation. Most tumors display tumor-specific antigens. One reason, however, why immunogenic tumors can escape host immunity is that tumor-reactive T cells receive inadequate costimulation. The introduction of the costimulatory

molecules, such as H4-1BB into the tumor, therefore, could enhance the antitumor immunity of cytotoxic T cells (CTL). H4-1BBL can be expressed in cell-specific fashion. For example, the H4-1BBL can be expressed in melanoma using melanocyte-specific promoter such as tyrosinase promoters. The H4-1BBL-expressing melanoma will stimulate cytotoxic T cells through H4-1BB and activate the melanoma-specific CTL. The activated melanoma-specific CTL can destroy melanoma.

Monoclonal Antibody to H4-BB

4-1 BB is expressed on activated but not resting murine T cells. Crosslinking of 1 AH2 mAb directed against murine 4-1 BB has been shown to enhance anti-CD3-induced T cell proliferation (41). Normal splenic cell antigen presentation and T cell activation can be blocked by inhibiting the binding of 4-1BB on T cells to its ligand on B cells and macrophages with 4-1 BB/AP, a fusion protein containing the extracellular domains of 4-1BB and alkaline phosphatase. We developed and here describe the characterization of 15 human 4-1BB specific mAbs: 4B4-1, 4B11 and 1G5. All mAb specifically bind human 4-1BB expressing SF-21 cells.

Production of recombinant human 4-1 BB

PGEX-3 expression vector (Pharmacia) containing the full length cDNA sequence 20 encoding 4-1 BB and the GST-binding domain of glutathione S transferase (GST) was constructed and the fusion protein expressed in bacteria. Fusing H4-1BB with GST, allowed for efficient purification of rH4-1BB when isolated by GST-sepharose and a Sepharose 4B column chromatographies. The GST-binding domain was cleaved prior to immunization. The rh4-1BB fraction was purified by GST-sepharose column and 25 Sepharose 4B column chromatographies and subsequently cleaved with factor Xa to release the h4-1 BB portion prior to immunization.

BALB/c animals were immunized with rh4-1 BB protein and their splenocytes were fused with the Sp2/o fusion partner. Eight week-old BALB/c mice were immunized with

50 µg of sh4-1 BB emulsified in Titermax (Cytok) or Complete Friends adjuvant. Three intraperitoneal (ip) injections were administered 2-weeks apart (42). Three days following the last injection, the mouse was sacrificed and their spleens were removed. Spleen cells were fused with Sp2/o myeloma cells. Spleen cells and Sp2/o cells were mixed at 5:1 ratio and fused using 50% PEG. Cells were washed, resuspended in OptiMEM (Gibco), 10% FCS, 5 mM hypoxanthine, 1 % aminopterin, and 0.8 mM thymidine (HAT) and cultured in 96 well U-bottom plates (Corning). Resulting cell supernatants were screened by ELISA for rh4-1 BB reactivity. Clones were isolated and subcloned.

Antibodies and reagents used

10 FITC-labeled goat anti-mouse mAb with specificity for the heavy chain of IgG and IgM (GAMGM)(Jackson Laboratories, MA) was used at 1:150. Tricolorlabeled anti-CD4, CD8, CD45RO, PE-labeled anti-CD3 mabs and isotype controls were purchased from CALTAG (S. San Francisco, CA) and used according to manufacturer's recommendations. 4B4-1 (IgG1) was purified over a protein-G sepharose column and
15 directly labeled by incubating the purified mAb in 0.4 mg/ml of FITC (Pierce) on ice for 3 hrs followed by filtration through Centricon-30 Microconcentrators (Amicon) to remove free-unbound FITC. FITC-labeled 4B4-1 was used at 3-4 µg per 5.0×10^5 cells for staining.

The resulting hybridomas supernatants were screened for binding to rh4-1 BB
20 protein by ELISA. Cell supernatants scoring positive for binding to rh4-1 BB by ELISA were subsequently assessed for staining of CEM (human T lymphoma) cells by FCM. CEM and 4B4-1, IG5, and 4B11 hybridoma cells were maintained in the basic culturing media. CEM cells were stimulated overnight to 48 hrs with 10 ng/ml PMA and 1 µM ionomycin in culturing media. Only 4B4-1 mAb specifically bound CEM cells above the
25 non-specific binding of the isotype control and only after the cells had been stimulated with 10 ng/ml PMA and 1 µM ionomycin for 24 hrs. All other mAb positive by ELISA for rh4-1 BB did not appear to bind CEM cells.

To conduct the immunoprecipitations, cell surface proteins were labeled with biotin as previously described (17). Briefly, 1×10^7 cells were washed in ice-cold PBS,

resuspended in freshly prepared 0.5 mg/ml animohexanoyl-biotin-N-hydroxysuccinimide ester (AH-BNHS, Zymed Lab., Inc) in PBS for 30 min at 4 C with constant agitation. Cells were washed twice with 0.2 M glycine in PBS. Cells were lysed on ice for 15 min in 200 µl lysis buffer containing 1.0% NP-40, 20 mM Tris-HCl, 0.15 NaCl, µM sodium orthovanadate, 5 µl/ml aprotinin and 1 µg/ml leupeptin, pH 7.5. Suspension was centrifuged at 14,000 rpm for 10 min, 4 C to remove debris. 20 µl of hybridoma culture supernatants were added for 1 hr, 4 C followed by the addition of 30 µl of a 50% suspension of protein G-Sepharose 4B (Zymed Lab, Inc.) and incubated for 1 hr, 4 C. Suspension was centrifuge and resulting protein G-Sepharose pellet was washed. The immunoprecipitates were boiled 5 min in 20 µl SDS sample buffer and run on 10% SDS-PAGE. Proteins were transfered to Immobilon-P membrane (Millipore Corp., Bedford, MA) and blocked with 5% BSA in buffer containing 25 mM Tris-HCl, 0.15 NaCl, 0.05% Tween 20, pH 7.5 (TBST). The blot was probed with avidin-horse radish peroxidase conjugate and developed using chemiluminescence detection kit (ECL, Amersham Corp., Arlington Heights, IL).

To conduct the Flow Cytometric studies (FCM) fresh cells were washed once and cultured cells were washed 3 times in staining media consisting of PBS, 1 % BSA and 0.1 % glucose prior to staining. Approximately $2.5-5 \times 10^5$ cells were resuspended in 50-100 µl of diluted mAb in staining media and incubated at 4 C for 30-60 min. Cells were washed once, resuspended in a 1:150 dilution of FITC-labeled GAMGM secondary mAb (Jackson Laboratories, MA) when needed, incubated 30 min and washed 3-4 times or simply washed 3-4 times if primary mAb were directly labeled. Cells were fixed with 1% paraformaldehyde for overnight prior to analysis on the FACScan by Becton Dickinson using Consort 30 or FACScan software. Appropriate isotype controls were included for all primary antibodies used. Gates were set on live cells only, based on forward versus side scatter profiles. Five to 15000 events were collected for each sample.

To further address whether 4B4-1 mAb specifically recognized 4-1 BB and to assess the specificity of the other mAb picked-up by ELISA, SF-21 insect cells were infected with baculovirus containing cDNA encoding h4-1 BB or an irrelevant protein.

SF-21 cells were grown in Grace Media (Gibco) supplemented with 10% FCS, 3.3 g/l yeastolate (Gibco), 3.3g/l lactalbumin hydrolysate(Gibco), 2 mM glutamine (Sigma) and antibiotics at 27 C.

5 Infected SF-21 insect cells were then analyzed by FCM for binding of the various mAbs. Only cells infected with the baclovirus containing and expressing products the h4-1 BB construct on the cell surface, but not the construct encoding and expressing an irrelevant protein were found to bind 4B4-1, 4B11 and IG5 mAbs. This data demonstrates that 4B4-1 mAb is specific for h4-1 BB. By immunoprecipitation, only 4B4-1 mAb precipitated a ~35 kDa protein when run on SDS-PAGE under reducing
10 conditions and ~70 kDa protein under non-reducing conditions from rh4-1 BB expressing SF-21 cells, but not those cells expressing irrelevant protein. Similar results were seen using CEM cells with PMA and ionomycin stimulation. IG5 is of an IgM isotype, thus explaining its apparent inability to immunoprecipitate rh4-1 BB. 4B4-1 and 4B11 mAb are IgGs.

15 To evaluate 4-1BB expression in human peripheral blood, mononuclear cells were isolated by passage over ficoll, washed and stained for with 4B4-1 mAb. Human peripheral blood mononuclear cells (PBMC) were isolated by Histopaque 1077 (Sigma) for 30 min at 400 g and the resulting interface cells were washed twice prior to use. Human T cells were isolated according to manufacturer's instructions. Briefly, PBMCs
20 were treated with Lympho-kwik (One Lambda, Ince., Canoga Park, CA) T cell isolation solution for 20 min at 37 C followed by a 5 min centrifugation at 1500 g. The resulting cell pellet was washed twice prior to use. PBMC or freshly isolated T cells were cultured in basic culturing media consisting of RPMI 1 640 (Gibco Laboratories), 10% FCS (Hyclone, Utah), 1 x MEM nonessential amino acids (Sigma), 1 mM sodium
25 pyruvate (Gibco), 2 mM glutamine(Sigma), and 50 U/ml penicillin and 50 µg/ml streptomycin (Gibco) supplemented with 5 Rg/ml PHA (Calbiochem) and 50 @ 2-ME (Sigma).

Of the lymphocyte sized fraction, <2% were positive for 4B4-1 mAb binding (data not shown) when compared to binding observed with an irrelevant-isotype control.
30 By multi-color analysis, <2% of CD3+ (T) cells were found to expressed 4-1 BB.

Isotype-matched irrelevant mAb were used for each fluorescence parameter to correct for non-specific binding of the mabs. By 48 hrs of PHA-stimulation, 18.5-21.5% of purified T cells expressed 4-1 BB on its cell surface. Without PHA-stimulation <2% of T cells express 4-1 BB. On PHA-stimulated T cells, 4-1BB was expressed on both
5 CD4+ and CD8+ cells with ~50% of 4-1 BB+ cells expressing CD4 and 50% expressing CD8.

Binding of 4B4-1 FITC-labeled mAb was almost completely blocked when PHA-stimulated T cells were pre-incubated with μ /ml purified rh4-1 BB protein, but not irrelevant control protein at similar concentration made in a similar manner.

10 PHA-stimulated T cells were incubated 30 min. on ice with staining media or varying concentrations of either rh4-1 BB protein or irrelevant recombinant protein that was produced in a similar manner as rh4-1 BB. Without washing 2.5 μ g of 4B4/FITC-labeled mAb or isotype matched FITC-labeled mAb, a suboptimal concentration, was added and cells were further incubated on ice for 30 min. Cells were washed 3 times
15 with staining media, fixed with 1 % paraformaldehyde, and analyzed by FCM as described above.

The competitive blocking of 4B4-1 /FITC mAb by rh4-1 BB was dependent upon the concentration of rh4-1 BB. Together this data demonstrates that 4B4-1 mAb specifically recognizes the human 4-1 BB on peripheral blood T cells.

20

Activated T cells co-express 4-1BB+ and CD45RA and CD45RO.

We have previously shown that murine 4-1BB is associated with p56^{lck} by a series of immunoprecipitation studies and peptide mapping study. During the course of these studies we observed that not only did anti-4-1 BB mAb coimmunoprecipitate a 56 kDa
25 protein but it also immunoprecipitated a protein of 200 kDa. Conversely, anti-CD45 mAb co-immunoprecipitated a ~30 kDa protein from ConA stimulated murine thymocytes. This data suggests that 4-1 BB may form a multi-peptide complex with CD45 and p56^{lck} on activated murine T cells. To assess the association of 4-1 BB and CD45 in humans,

PBMCs stimulated with PHA for 48 hrs were analyzed for expression of CD45RA and CD45RO isoforms by multi-color FCM. Sixteen to 19% of cells expressed 4-1 BB, and nearly all (except 1%) expressed CD45RA and nearly all express CD45RO after correcting for non-specific binding of the antibodies.

5

Discussion of Examples of Uses for mAb 4B4-1.

The 4B4-1 mAb specifically stained the T cell line, CEM and peripheral blood T cells following activation, but did not bind resting cells. In this regard, 4-1BB expression in humans is similar to that observed in the mouse. 4B4-1 mAb immunoprecipitates a
10 homodimeric protein of ~35 kDa under reducing conditions and ~70 kDa under non-reducing conditions from 4-1 BB expressing SF-21 cells and activated CEM cells. The molecular weights are similar to the expected values based on amino acid sequence and anticipated glycosylation and similar to molecular weight observed in the mouse. Furthermore, 10 µg of rh4-1 BB protein, but not irrelevant protein, completely block the
15 binding of FITC-labeled 4B4-1 mAb to PHA stimulated T cells. Collectively, these data conclusively show that 4B4-1 mAb is specific for human 4-1 BB.

Although 4B 11 and I G5 mAbs specifically recognize 4-1 BB expressed on SF-21 cells, they do not recognize 4-1 BB expressed on activated T cells. This is most likely due to the mAb having specificity for a cryptic or unique binding site(s) that is not exposed or
20 present on T-cells but is accessible or present on SF-21 cells due to slight differences in glycosylation and processing between human T cells and insect cells (SF-21).

In mice, neither 4-1BB mRNA nor surface expression is detectable on resting splenocytes or unstimulated cloned T cells. But upon activation of T cells by anti-CD3 or antiTCRαβ, 4-1 BB mRNA is detected within 3 hrs of stimulation and is first detectable
25 on the cell surface 2-3 days following stimulation. Maximum surface expression is reached about 6 days following stimulation. As in the mouse, 4-1 BB is not detected on the surface of freshly isolated peripheral blood T cells in man, but is readily detected following PHA-stimulation. Unlike in the mouse, 4-1BB is expressed much more rapidly in humans, reaching a peak expression level within 12-48 hrs. 4-1BB expression begins to

decrease within 72 hrs poststimulation, as do the number of cells expressing 4-1 BB on their cell surface. In both mouse and humans, 4-1 BB is expressed on CD4+ and CD8+ T cell subsets) (19).

4-1 BB is associated with p56^{lck}. A 56 kDa protein is detected when ³²PO₄ was transferred from gamma-labeled ATP onto the p56 protein in ConA activated thymocytes that were subjected to immunoprecipitated with anti-4-1 BB mAb, 1AH2. By peptide mapping, this 56 kDa phosphoprotein was identified as p56^{lck}. p56^{lck} and 4-1 BB was also be found to co-immunoprecipitate from insect cells (SF-21) and HeLa cells transfected with 4-1BB and p56^{lck}. Furthermore, cross-linking of 4-1BB activated p56^{lck}. Cysteine residues critical for p56^{lck}-CD4/CD8 complex formation were also critical for p56^{lck}-4-1BB interaction. In preliminary results, it was noted that anti-4-1BB also immunoprecipitated a protein of ~200 kDa from biotin-surface labeled ConA activated thymocytes. When anti-CD45 mAb was used for immunoprecipitation, a ~30 kDa protein, of similar size to murine 4-1BB, was detected. Other have previously shown that CD45 mediates the dephosphorylation of certain proteins such as p56^{lck} (44). Perhaps 4-1 BB plays a role in bringing CD45 and p56^{lck} together and facilitates the dephosphorylation of p56^{lck} by the CD45 phosphatase.

To further assess the association of 4-1 BB and CD45, PHA-stimulated PBMCs were analyzed by multicolor FCM. Approximately 16-19% of PBMCs cultured in PHA for 48 hrs express 4-1 BB. If all 4-1BB+ cells express CD45RA (Figure 7A) and express CD45RO, the ~17.5% of 4-1BB+ cells must co-express both CD45RA and CD45RO on their cell surface. Of the PHA-stimulated CD45RA^{hi}RO^{hi} cells, approximately 50% express 4-1 BB. This data further supports the hypothesis that CD45 and 4-1BB share an association. More importantly, it suggests that 4-1 BB may play a role in T cell transition from a naive phenotype (CD45RA^{hi}RO^{lo}) to a memory phenotype (CD45RA^{lo}RO^{hi}). Picker et al. previously demonstrated through multi-color FCM, that naive T cells undergo a "stepwise, unidirectional progression" from a naive (CD45RA^{lo}RO^{hi}) to a memory (CD45RA^{lo}RO^{hi}) phenotype through a distinct CD45RA^{hi}RO^{hi} intermediate cell type (21). Peripheral blood few cells that express this intermediate phenotype are detectable. However, in secondary lymphoid tissue, such as tonsil, 2-10% of T cells were found to be

CD45RA^{hi}RO^{hi}. Much is known about the naive and memory T cells, but little is known about the CD45RA^{hi}RO^{hi} in transitional cells. Nor is it known what events occur during this transition phase that result in memory T cell development. Therefore, it will be necessary to assess the role of 4-1 BB in the transition from a naive to that of a memory T cell and the apparent association of 4-1 BB and CD45. In this regard, 4B4-1 mAb will be invaluable.

The mAb 4B4-1 can be used to enhance T-cell cross-linking and therefore induce T-cell activation against certain types of cancer cells (e.g. melanoma). By using the mAb in experiments with various cancer cells in the presence of T-cells dosages and proper formulations of initiating T-cell activation against the cancer cells can be determined. The formulations are tested in animal models with the same type of cancer and the formulations and dosages are refined for testing in humans.

Sinovial T-lymphocytes in patients with rheumatoid arthritis express H4-1BB, but 4-1BB is not expressed in sinovial T-lymphocytes of patients without this disease. This disease involves an undesired immune response against the patient's own tissue. Therefore, blocking the undesired immune response would provide relief for the arthritis sufferer. By injecting the patient with the mAb 4B1-4 or the fusion protein, the binding between H4-1BB and its ligand would be blocked. If the binding of the mAb and H4-1BB did not enhance activation of the immune system, then the mAb 4B1-4 interference with binding would have the desired effect, otherwise the fusion protein would be used for blocking binding. The fusion protein (monomeric) does not stimulate H4-1BB or its ligand but is a good ligand binding blocker because it binds to the H4-1BB ligand thereby preventing H4-1BB from binding and stimulating the ligand.

A similar method of blocking ligand binding would be useful for treating patients with systemic lupus erythematosus. For patients with Type I diabetes - T-cells attack their own insulin producing cells, pancreatic Beta cells. By injecting the mAb or fusion protein this destruction can be blocked.

Peripheral blood T cells in patients with AIDS or certain types of viral flu are expressing H4-1BB, whereas the same cells in normal patients are not expressing H4-1BB.

Therefore, 4-1BB is important in this immune response. The enhancement or blocking of H4-1BB ligand binding or cross-linking will be important in regulating the T-cells in patients with these diseases.

5 APPENDIX A - REFERENCES

1. Smith, C.A., Davis, T., Anderson, D., Solam, L., Beckmann, M.P., Jerzy, R., Dower, S.K., Cosman, D., and Goodwin, R.G. 1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. *Science* 248:1019-1023.
2. Ebina, Y., L. Ellis, K. Jaruagin, M. Edery, L. Graf, E. Clauser, J. On, F. Marizrz, Y.W. Kan, J.D. Goldfine, R.A. Roth and W.J. Rutter, 1985, The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling, *Cell* 40:747.
3. Vassali, R., R. Tedghi, B. Listowska-Bernstein, A. Tartakoff and J.C. Jaton, 1979, Evidence for hydrophobic region within heavy chains of mouse B lymphocyte membrane-bound IgM, *Proc. Natl. Acad. Sci. USA* 76:5515.
4. Haskins, K., R. Kubo, J. White, M. Pigeon, J. Kappler and P. Marrack, 1983, The major histocompatibility complex-restricted antigen receptor on T cells I Isolation with monoclonal antibody, *J. Exp. Med.* 157:1149.
5. Lesslaver, W. and H. Gmunder, 1986, Biochemical characterization of the 9.3 antigens of human T-cells: simultaneous expression of disulfide-bonded 90-Kiladalton dimers and free subunits at the cell surface, *Mol. Immunol.* 23:271.
6. Van Lier, R., J. Borst, T. Vroom, H. Klein, P. Mourik, W. Zeijlemaker and C. Melife, 1987, Tissue distribution and biochemical and functional properties of Tp55 (CD27) a novel T cell differentiation antigen, *J. Immunol.* 139:1589.
7. Mallett, S., S. Fossum and A. Barclay, 1990, Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor, *EMBO J.* 9:1603.
8. Banchereau, J., P. Paoli, A., Valle, E. Garcia and F. Roussel, 1991, Long-term human B cell lines dependent on interleukin-4 and antibody to CD40, *Science* 251:70.
9. Moeller, D.L., M.K. Jenkins and R.H. Schwartz, 1989, Clonal expansion versus functional clonal inactivation: a co-stimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy, *Ann. Rev. Immunol.* 7:445.
10. June, D.H., J.A. Ledbetter, P.S. Linsley and C.B. Thompson, 1989, Role of CD28 receptor in T cell activation, *Immunol. Today* 11:211.

11. Yang, L., B. Jones, A. Aruffo, K.M. Sullivan, P.S. Linsley and C.A. Janeway, Jr., 1992, Heat stable antigen is a co-stimulatory molecule for CD4 T cell growth, *J. Exp. Med.* 175:437.
- 5 12. Yamori, T., 1992, Molecular mechanisms for generation of neural diversity and specificity: roles of polypeptide factors in development of post-mitotic neurons, *Neurosci. Res.* 12:545.
13. Liu, Y.J., D.E. Joshua, G.T. Williams, C.A. Smith, J. Gordon and I.C. M. MacLennan, 1989, Mechanism of antigen-driven selection in germinal centres, *Nature*, 342:929.
- 10 14. Jabara, H. H., s. M. Fu, R.S. Geha and D. Vercelli, 1990, CD40 and IfE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells, *J. Exp. Med.* 172:1861.
- 15 15. Defrance, R., B. Vanbervliet, F. Briere, I. Durnad, F. Roussle and J. Banchereau, 1992, Interleukin 10 and transforming growth factor b cooperate to induce anti-CD40 activated naive human B cells to secrete immunoglobulin A, *J. Exp. Med.* 175:671.
- 20 16. Donahue, T., Cigan, A., Pahich, E. and Valavicius, B., Mutations at a Zn(II) finger motif in the yeast eIF-2b gene alter ribosomal start-site selection during the scanning process, *Cell* 54 (1988) 621-632.
17. Carthew, R.W and Rubin, G.M., seven in absentia, a gene required for specification of R7 cell fate in the *Drosophila* eye, *Cell*, 63 (1990) 561-577.
- 25 18. Driscoll, D.M. and Williams, J.G., Two divergently transcribed genes of *Dictyostelium discoideum* are cyclic AMP-inducible and coregulated during development, *Mol. and Cell. Biol.* 7 (1987) 4482-4489.
- 30 19. Chalupny, N.J., Peach, R., Hollenbaugh, D., Ledbetter, J.A., Farr, A.G. and Aruffo, A., 1992, *Proc. Natl. Acad. Sci USA* 89:10360-10364.
20. Noelle, R.J., and Snow, E.C., 1991, *The FASEB J.* 5:2770-2776.
- 35 21. Noelle, R. and Snow, E., 1990, *Immunol. Today* 11:361-368.
22. Zurawski, G., Benedik, M., Kamb, B.J., Abrams, J.S., Zurawski, S.M. and Lee, F.D. (1986) *Science* 232:772-775.
- 40 23. Kinachi, T. (1986) *Nature* 325,70-73.
24. Gershenfeld, H.K. and Weissman, I.L. *Science* (1986) 232,854-858.
- 45 25. Biggin, M., Gison, T. and Hung, G. (1983) *Proc. Natl. Acad. Sci. USA* 80,3963-3965.
26. Hodgkin, P.D., Yamashita, L.C., Coffman, R.L. and Kehry, M.R., 1990, *J. Immunol.* 145:2025-2034.

27. Barlett, W.C., McCann, J., Shephaer, D.M., Roy, M. and Noelle, R.J., 1990, J. Immunol. 145:3956-3962.
- 5 28. Kwon, B.S., Kestler, D.P., Eshhar, Z., Oh, K., and Wakulchik, M. 1989. Expression characteristics of two potential T cell mediator genes. Cell. Immunol. 121:414-422.
29. Armitage, R., Fanslow, W., Strockbine, L., Sato, T., Clifford, K., MacDuff, B., Anderson, D., Gimpel, S., Davis-Smith, T., Maliszewski, C., Clark, E., Smith, C.,
10 Grabstein, K., Cosman, D. and Spriggs, M., 1991, Nature 357:80-82.
30. Kwon, B., Kestler, D., Lee, E., Wakulchik, M. and Young J. (1988) J. Exp. Med (1988) (In press).
- 15 31. Noelle, R.J., Roy, M., Shepherd, D.M., Stamenkovic, I., Ledbetter, J.A. and Aruffo, A., 1992, Proc. Natl. Acad. Sci. USA 89:6550-6554.
32. Hollenbaugh, D., Grosmaier, L.S., Kullas, C.D., Chalupny, N.J., Braesch-Andersen, S., Noelle, R.J., Stamenkovic, I., Ledbetter, J.A. and Aruffo, A., 1992, EMBO 11:4314-4321.
20
33. Schall, T.J., M. Lewis, K.J. Koller, A. Lee, G.C. Rice, G.H. W. Wong, T. Gatanaga, G.A. Granger, R. Lentz, H. Raab, W.J. Kohr and D.V. Goeddel, 1990, Molecular cloning and ex8pression of a receptor for human tumor necrosis factor, Cell 61:361.
- 25 34. Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K.R., Reichardt, L.F. and Barbacid, M., 1991, Cell 66:395-403.
35. Armitage, R.J., Sato, T.A., Macduff, B.M., Clifford, K.N., Alpert, A.R., Smith, C.A. and Fanslow, W.C., 1992, Eu8r. J. Immunol. 22:2071-2076.
30
36. Hintzen, R.Q., deJong, R., Hack, E.E., Chamuleau, M., de Vries, E.F.R., ten Berge, I.J.M., Borst, J. and van Lier, R.A.W., 1991, J. Immunol. 147:29-35.
37. Mallett, S., and Barclay, A.N. 1991. A new super-family of cell surface proteins related
35 to the nerve growth factor receptor. Immunol. Today. 12:220-223.
38. Kwon, B.S., and Weissman, S.M. 1989. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA. 86:1963-1967.
- 40 39. Johnson, D., Lanahan, A., Buck C.R., Sehgal, A., Morgan, C., Mercer, E., Bothwell, M., and Chao, M. 1986. Expression and structure of the human NGF receptor. Cell 47:545-554.
- 45 40. Stamenkovic, I., Clark, E., and Seed, B. 1989. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO. J. 8:1403-1408.

41. Pollok KE, Y-J Kim, Z Zhou, J Hurtado, KK Kim, and BS Kwon. 1993. The inducible T cell antigen 4-1 BB: Analysis of expression and function. *J Immunol* 150:771.
42. Antibody Lab Manual. 1988. Editors are E Harlow and D Lane. Cold Spring Harbor Lab.
43. Pelchen-Matthews, A, JE Armes, G Griffiths, and M Marsh. 1991. Differential endocytosis of CD4 in lymphocytic and nonlymphocytic cells. *J Exp Med* 173:575.
44. Biffen, M, D McMichael-Phillips, T Larson, A Venkitaraman, and D Alexander. 1994. The CD45 tyrosine phosphatase regulates specific pools of antigen receptor-associated P59fyn and CD4-associated p56lck tyrosine kinases in human T-cells. *EMBO J* 13:1920.

15

APPENDIX B COMMON ABBREVIATIONS

- | | | |
|----|-----------|--|
| 20 | CTL | cytolytic T lymphocyte |
| | HTL | helper T lymphocyte |
| | LGL | large granular lymphocytes |
| | NK | natural killer cells |
| | ConA | concanavalin A |
| 25 | DTT | dithiothreitol |
| | mAb | monoclonal antibody. |
| | 4-1BB | protein expressed on activated T cells |
| | rh) 4-1BB | recombinant human 4-1BB |
| | 4-1BB/L | ligand to 4-1BB found on activated macrophage and mature B cells |
| 30 | 4-1BB/AP | fusion protein between 4-1BB and alkaline phosphatase. |
| | SDS | sodium dodecylsulfate |
| | SSC | 150 mM sodium chloride/15 mM sodium citrate, pH 7.0 |
| | TPA | 12-O-tetradecanoylphorbol-13-acetate |
| | Th | helper T lymphocytes |
| 35 | IL-2 | interleukin 2 |
| | IL-3 | interleukin 3 |
| | rIL-2 | recombinant IL-2 |
| | CSF-GM | granulocyte/macrophage colony-stimulating factors |
| | cRNA | complementary RNA |
| 40 | ss | single-stranded |
| | ds | double-stranded |
| | TCR | T-cell antigen receptor |
| | PTA | phorbol 12-tetradecanoate 13-acetate |
| | r | recombinant |
| 45 | mu | murine |
| | hu | human |
| | BFU-E | burst forming unit-erythroid, an erythroid progenitor cell |
| | CFU-GEMM | colony forming unit-granulocyte erythroid macrophage |

	CFU-GM	megakaryocyte, a multipotential progenitor cell colony forming unit-granulocyte macrophage, a granulocyte- macrophage progenitor cell
	CFU-S	colony forming unit-Spleen, a multipotential stem cell
5	H-ferritin	the heavy chain subunit form of ferritin
	MGF	mast cell growth factor, a c-kit ligand
	CSF	colony stimulating factors
	G	granulocyte
	M	macrophage
10	Epo	erythropoietin
	IL	interleukin
	LD	low density
	NALDT	non-adherent low density T-lymphocyte depleted
	PMSF	phenylmethylsulfonyl fluoride
15	PBS	phosphate buffered saline
	AcNPV	<i>Autographa californica</i> nuclear polyhedrosis virus
	SDS	sodium dodecyl sulfate
	LPS	lipopolysaccharide

- 20 The foregoing description has been directed to particular embodiments of the invention in accordance with the requirements of the Patent Statutes for the purposes of illustration and explanation. It will be apparent, however, to those skilled in this art that many modifications and changes will be possible without departure from the scope and spirit of the invention. It is intended that the following claims be interpreted to embrace
- 25 all such modifications.

SEQUENCE LISTING

- 5 (1) GENERAL INFORMATION:
- (i) APPLICANT: Kwon, Byoung Se
Kang, Chang-Yuil
- 10 (ii) TITLE OF INVENTION: Monoclonal antibody against human
receptor 4-1BB
- (iii) NUMBER OF SEQUENCES: 10
- 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Barnard, Brown & Michaels
(B) STREET: 306 East State Street, Suite 220
(C) CITY: Ithaca
(D) STATE: NY
20 (E) COUNTRY: USA
(F) ZIP: 14850
- (v) COMPUTER READABLE FORM:
25 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
30 (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
35 (A) APPLICATION NUMBER: US 08/122,796
(B) FILING DATE: 16-SEP-1993
- (vii) PRIOR APPLICATION DATA:
40 (A) APPLICATION NUMBER: US 08/012,269
(B) FILING DATE: 01-FEB-1993
- (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 07/922,996
(B) FILING DATE: 30-JUL-1992
- 45 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 07/267,577
(B) FILING DATE: 07-NOV-1988
- 50 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Michaels, Christopher A
(B) REGISTRATION NUMBER: 34,390
(C) REFERENCE/DOCKET NUMBER: KW05
- 55 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 607-273-1711
(B) TELEFAX: 607-273-2609
- 60 (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2347 base pairs
(B) TYPE: nucleic acid
65 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: murine 4-1BB

5 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 146..916

10 (ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 146..913

15 (x) PUBLICATION INFORMATION:
 (A) AUTHORS: Kwon, Byoung Se
 et al.,
 (B) TITLE: cDNA sequences of two inducible T-cell genes
 (C) JOURNAL: Proc. Natl. Acad. Sci. U.S.A.
 (D) VOLUME: 86
 20 (E) ISSUE: March
 (F) PAGES: 1963-1967
 (G) DATE: 1989
 (K) RELEVANT RESIDUES IN SEQ ID NO:1: FROM 1 TO 2347

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGTCCATGA ACTGCTGAGT GGATAAACAG CACGGGATAT CTCTGTCTAA AGGAATATTA	60
30 CTACACCAGG AAAAGGACAC ATTCGACAAC AGGAAAGGAG CCTGTCACAG AAAACCACAG	120
TGTCCTGTGC ATGTGACATT TCGCC ATG GGA AAC AAC TGT TAC AAC GTG GTG	172
Met Gly Asn Asn Cys Tyr Asn Val Val	
1 5	
35 GTC ATT GTC CTG CTG CTA GTG GGC TGT GAG AAG GTG GGA GCC GTG CAG	220
Val Ile Val Leu Leu Val Gly Cys Glu Lys Val Gly Ala Val Gln	
10 15 20 25	
40 AAC TCC TGT GAT AAC TGT CAG CCT GGT ACT TTC TGC AGA AAA TAC AAT	268
Asn Ser Cys Asp Asn Cys Gln Pro Gly Thr Phe Cys Arg Lys Tyr Asn	
30 35 40	
45 CCA GTC TGC AAG AGC TGC CCT CCA AGT ACC TTC TCC AGC ATA GGT GGA	316
Pro Val Cys Lys Ser Cys Pro Pro Ser Thr Phe Ser Ser Ile Gly Gly	
45 50 55	
50 CAG CCG AAC TGT AAC ATC TGC AGA GTG TGT GCA GGC TAT TTC AGG TTC	364
Gln Pro Asn Cys Asn Ile Cys Arg Val Cys Ala Gly Tyr Phe Arg Phe	
60 65 70	
AAG AAG TTT TGC TCC TCT ACC CAC AAC GCG GAG TGT GAG TGC ATT GAA	412
Lys Lys Phe Cys Ser Ser Thr His Asn Ala Glu Cys Glu Cys Ile Glu	
75 80 85	
55 GGA TTC CAT TGC TTG GGG CCA CAG TGC ACC AGA TGT GAA AAG GAC TGC	460
Gly Phe His Cys Leu Gly Pro Gln Cys Thr Arg Cys Glu Lys Asp Cys	
90 95 100 105	
60 AGG CCT GGC CAG GAG CTA ACG AAG CAG GGT TGC AAA ACC TGT AGC TTG	508
Arg Pro Gly Gln Glu Leu Thr Lys Gln Gly Cys Lys Thr Cys Ser Leu	
110 115 120	
65 GGA ACA TTT AAT GAC CAG AAC GGT ACT GGC GTC TGT CGA CCC TGG ACG	556
Gly Thr Phe Asn Asp Gln Asn Gly Thr Gly Val Cys Arg Pro Trp Thr	
125 130 135	
AAC TGC TCT CTA GAC GGA AGG TCT GTG CTT AAG ACC GGG ACC ACG GAG	604

	Asn	Cys	Ser	Leu	Asp	Gly	Arg	Ser	Val	Leu	Lys	Thr	Gly	Thr	Thr	Glu	
	140							145					150				
5	AAG	GAC	GTG	GTG	TGT	GGA	CCC	CCT	GTG	GTG	AGC	TTC	TCT	CCC	AGT	ACC	652
	Lys	Asp	Val	Val	Cys	Gly	Pro	Pro	Val	Val	Ser	Phe	Ser	Pro	Ser	Thr	
	155					160					165						
10	ACC	ATT	TCT	GTG	ACT	CCA	GAG	GGA	GGA	CCA	GGA	GGG	CAC	TCC	TTG	CAG	700
	Thr	Ile	Ser	Val	Thr	Pro	Glu	Gly	Gly	Pro	Gly	Gly	His	Ser	Leu	Gln	
	170					175					180					185	
15	GTC	CTT	ACC	TTG	TTC	CTG	GCG	CTG	ACA	TGG	GCT	TTG	CTG	CTG	GCC	CTG	748
	Val	Leu	Thr	Leu	Phe	Leu	Ala	Leu	Thr	Ser	Ala	Leu	Leu	Leu	Ala	Leu	
					190					195					200		
	ATC	TTC	ATT	ACT	CTC	CTG	TTC	TCT	GTG	CTC	AAA	TGG	ATC	AGG	AAA	AAA	796
	Ile	Phe	Ile	Thr	Leu	Leu	Phe	Ser	Val	Leu	Lys	Trp	Ile	Arg	Lys	Lys	
				205					210					215			
20	TTC	CCC	CAC	ATA	TTC	AAG	CAA	CCA	TTT	AAG	AAG	ACC	ACT	GGA	GCA	GCT	844
	Phe	Pro	His	Ile	Phe	Lys	Gln	Pro	Phe	Lys	Lys	Thr	Thr	Gly	Ala	Ala	
				220				225					230				
25	CAA	GAG	GAA	GAT	GCT	TGT	AGC	TGC	CGA	TGT	CCA	CAG	GAA	GAA	GAA	GGA	892
	Gln	Glu	Glu	Asp	Ala	Cys	Ser	Cys	Arg	Cys	Pro	Gln	Glu	Glu	Glu	Gly	
	235					240						245					
30	GGA	GGA	GGA	GGC	TAT	GAG	CTG	TGA	TGTACTATCC	TAGGAGATGT	GTGGGCCCGAA						946
	Gly	Gly	Gly	Gly	Tyr	Glu	Leu	*									
	250					255											
35	ACCGAGAAGC	ACTAGGACCC	CACCATCCTG	TGGAACAGCA	CAAGCAACCC	CACCACCCTG											1006
	TTCTTACACA	TCATCCTAGA	TGATGTGTGG	GCGCGCACCT	CATCCAAGTC	TCTTCTAACG											1066
	CTAACATATT	TGCTTTTACC	TTTTTTTAAAT	CTTTTTTTTAA	ATTTAAATTT	TATGTGTGTG											1126
	AGTGTTTTGC	CTGCCTGTAT	GCACACGTGT	GTGTGTGTGT	GTGTGTGACA	CTCCTGATGC											1186
40	CTGAGGAGGT	CAGAAGACAA	AGGGTTGGTT	CCATAAGAAC	TGGAGTTATG	GATGGCTGTG											1246
	AGCCGGGATA	GGTCGGGACG	GAGACCTGTC	TTCTTATTTT	AACGTGACTG	TATAATAAAA											1306
45	AAAAAATGAT	ATTTTCGGGAA	TTGTAGAGAT	TGTCCTGACA	CCCTTCTAGT	TAATGATCTA											1366
	AGAGGAATTG	TTGATACGTA	GTATACTGTA	TATGTGTATG	TATATGTATA	TGTATATATA											1426
	AGACTCTTTT	ACTGTCAAAG	TCAACCTAGA	GTGTCTGGTT	ACCAGGTCAA	TTTTATTGGA											1486
50	CATTTTACGT	CACACACACA	CACACACACA	CACACACACG	TTTATACTAC	GTA CTGTTAT											1546
	CGGTATTCTA	CGTCATATAA	TGGGATAGGG	TAAAAGGAAA	CCAAAGAGTG	AGTGATATTA											1606
55	TTGTGGAGGT	GACAGACTAC	CCCTTCTGGG	TACGTAGGGA	CAGACCTCCT	TCGGACTGTC											1666
	TAAAAC TCCC	CTTAGAAGTC	TCGTCAAGTT	CCCGGACGAA	GAGGACAGAG	GAGACACAGT											1726
	CCGAAAAGTT	ATTTTCCGG	CAAATCCTTT	CCCTGTTTCG	TGACACTCCA	CCCCTTGTGG											1786
60	ACACTTGAGT	GTCATCCTTG	CGCCGGAAGG	TCAGGTGGTA	CCCGTCTGTA	GGGGCGGGGA											1846
	GACAGAGCCG	CGGGGGAGCT	ACGAGAATCG	ACTCACAGGG	CGCCCCGGGC	TTCGCAAATG											1906
65	AAACTTTTTT	AATCTCACAA	GTTTCGTCCG	GGCTCGGCGG	ACCTATGGCG	TCGATCCTTA											1966
	TTACCTTATC	CTGGCGCCAA	GATAAAACAA	CCAAAAGCCT	TGACTCCGGT	ACTAATTCTC											2026
	CCTGCCGGCC	CCCGTAAGCA	TAACGCGGCG	ATCTCCACTT	TAAGAACCTG	GCCGCGTTCT											2086

GCCTGGTCTC GCTTTCGTAA ACGGTTCTTA CAAAAGTAAT TAGTTCTTGC TTTCAGCCTC 2146
 5 CAAGCTTCTG CTAGTCTATG GCAGCATCAA GGCTGGTATT TGCTACGGCT GACCGCTACG 2206
 CCGCCGCAAT AAGGGTACTG GCGGCCCCGT CGAAGGCCCT TTGGTTTCAG AAACCCAAGG 2266
 CCCCCCTCAT ACCAACGTTT CGACTTTGAT TCTTGCCGGT ACGTGGTGGT GGGTGCCTTA 2326
 10 GCTCTTTCTC GATAGTTAGA C 2347

(2) INFORMATION FOR SEQ ID NO:2:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 257 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

25 Met Gly Asn Asn Cys Tyr Asn Val Val Val Ile Val Leu Leu Leu Val
 1 5 10 15
 Gly Cys Glu Lys Val Gly Ala Val Gln Asn Ser Cys Asp Asn Cys Gln
 20 25 30
 30 Pro Gly Thr Phe Cys Arg Lys Tyr Asn Pro Val Cys Lys Ser Cys Pro
 35 40 45
 Pro Ser Thr Phe Ser Ser Ile Gly Gly Gln Pro Asn Cys Asn Ile Cys
 50 55 60
 35 Arg Val Cys Ala Gly Tyr Phe Arg Phe Lys Lys Phe Cys Ser Ser Thr
 65 70 75 80
 40 His Asn Ala Glu Cys Glu Cys Ile Glu Gly Phe His Cys Leu Gly Pro
 85 90 95
 Gln Cys Thr Arg Cys Glu Lys Asp Cys Arg Pro Gly Gln Glu Leu Thr
 100 105 110
 45 Lys Gln Gly Cys Lys Thr Cys Ser Leu Gly Thr Phe Asn Asp Gln Asn
 115 120 125
 Gly Thr Gly Val Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Arg
 130 135 140
 50 Ser Val Leu Lys Thr Gly Thr Thr Glu Lys Asp Val Val Cys Gly Pro
 145 150 155 160
 55 Pro Val Val Ser Phe Ser Pro Ser Thr Thr Ile Ser Val Thr Pro Glu
 165 170 175
 Gly Gly Pro Gly Gly His Ser Leu Gln Val Leu Thr Leu Phe Leu Ala
 180 185 190
 60 Leu Thr Ser Ala Leu Leu Leu Ala Leu Ile Phe Ile Thr Leu Leu Phe
 195 200 205
 Ser Val Leu Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys Gln
 210 215 220
 65 Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Asp Ala Cys Ser
 225 230 235 240

Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly Tyr Glu Leu
 245 250 255

5

(2) INFORMATION FOR SEQ ID NO:3:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 15 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "PCR Primer"
- (iii) HYPOTHETICAL: NO
- 20 (iv) ANTI-SENSE: NO

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTYTGymGAA ARTAYAAyCC

20

30 (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 35 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "PCR Primer"
- 40 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

50 TTYTCSTSCA HTGGTGGACA

20

(2) INFORMATION FOR SEQ ID NO:5:

- 55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 60 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "PCR Primer"
- (iii) HYPOTHETICAL: NO
- 65 (iv) ANTI-SENSE: NO

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCCARGSWRC AGGTYTTTCA

20

5 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

15 (A) DESCRIPTION: /desc = "PCR Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

20

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:6:

25 TTYTGRTTCRT TRATGTTCC

20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 838 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

40 (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- 45 (A) ORGANISM: Homo sapiens
(C) INDIVIDUAL ISOLATE: H4-1BB #1
(D) DEVELOPMENTAL STAGE: Differentiated T-cell
(G) CELL TYPE: Lymphocyte

(ix) FEATURE:

- 50 (A) NAME/KEY: CDS
(B) LOCATION: 41..805
(D) OTHER INFORMATION: /codon_start= 41
/product= "H4-1BB"
/number= 1

(ix) FEATURE:

- 55 (A) NAME/KEY: mat_peptide
(B) LOCATION: 41..802
(D) OTHER INFORMATION: /codon_start= 41
/product= "H4-1BB"
/number= 1

60

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:7:

65 AATCAGCTTT GCTAGTATCA TACCTGTGCC AGATTTTCATC ATG GGA AAC AGC TGT
Met Gly Asn Ser Cys
1 5

55

TAC AAC ATA GTA GCC ACT CTG TTG CTG GTC CTC AAC TTT GAG AGG ACA

103

	Tyr	Asn	Ile	Val	Ala	Thr	Leu	Leu	Leu	Val	Leu	Asn	Phe	Glu	Arg	Thr	
				10						15						20	
5	AGA	TCA	TTG	CAG	GAT	CCT	TGT	AGT	AAC	TGC	CCA	GCT	GGT	ACA	TTC	TGT	151
	Arg	Ser	Leu	Gln	Asp	Pro	Cys	Ser	Asn	Cys	Pro	Ala	Gly	Thr	Phe	Cys	
				25					30					35			
10	GAT	AAT	AAC	AGC	AAT	CAG	ATT	TGC	ACT	CCC	TGT	CCT	CCA	AAT	AGT	TTC	199
	Asp	Asn	Asn	Arg	Asn	Gln	Ile	Cys	Ser	Pro	Cys	Pro	Pro	Asn	Ser	Phe	
				40				45					50				
15	TCC	AGC	GCA	GGT	GGA	CAA	AGG	ACC	TGT	GAC	ATA	TGC	AGG	CAG	TGT	AAA	247
	Ser	Ser	Ala	Gly	Gly	Gln	Arg	Thr	Cys	Asp	Ile	Cys	Arg	Gln	Cys	Lys	
				55			60					65					
20	GGT	GTT	TTC	AGG	ACC	AGG	AAG	GAG	TGT	TCC	TCC	ACC	AGC	AAT	GCA	GAG	295
	Gly	Val	Phe	Arg	Thr	Arg	Lys	Glu	Cys	Ser	Ser	Thr	Ser	Asn	Ala	Glu	
				70			75				80					85	
25	TGT	GAC	TGC	ACT	CCA	GGG	TTT	CAC	TGC	CTG	GGG	GCA	GGA	TGC	ACC	ATG	343
	Cys	Asp	Cys	Thr	Pro	Gly	Phe	His	Cys	Leu	Gly	Ala	Gly	Cys	Ser	Met	
					90					95					100		
30	TGT	GAA	CAG	GAT	TGT	AAA	CAA	GGT	CAA	GAA	CTG	ACA	AAA	AAA	GGT	TGT	391
	Cys	Glu	Gln	Asp	Cys	Lys	Gln	Gly	Gln	Glu	Leu	Thr	Lys	Lys	Gly	Cys	
				105				110						115			
35	AAA	GAC	TGT	TGC	TTT	GGG	ACA	TTT	AAC	GAT	CAG	AAA	CGT	GGC	ATC	TGT	439
	Lys	Asp	Cys	Cys	Phe	Gly	Thr	Phe	Asn	Asp	Gln	Lys	Arg	Gly	Ile	Cys	
				120				125					130				
40	CGA	CCC	TGG	ACA	AAC	TGT	TCT	TTG	GAT	GGA	AAG	TCT	GTG	CTT	GTG	AAT	487
	Arg	Pro	Trp	Thr	Asn	Cys	Ser	Leu	Asp	Gly	Lys	Ser	Val	Leu	Val	Asn	
				135			140					145					
45	GGG	ACG	AAG	GAG	AGG	GAC	GTG	GTC	TGT	GGA	CCA	TCT	CCA	GCT	GAC	CTC	535
	Gly	Thr	Lys	Glu	Arg	Asp	Val	Val	Cys	Gly	Pro	Ser	Pro	Ala	Asp	Leu	
				150			155				160					165	
50	TCT	CCG	GGA	GCA	TCC	TCT	GTG	ACC	CCG	CCT	GCC	CCT	GCG	AGA	GAG	CCA	583
	Ser	Pro	Gly	Ala	Ser	Ser	Val	Thr	Pro	Pro	Ala	Pro	Ala	Arg	Glu	Pro	
					170					175					180		
55	GGA	CAC	TCT	CCG	CAG	ATC	ATC	TCC	TTC	TTT	CTT	GCG	CTG	ACG	TCG	ACT	631
	Gly	His	Ser	Pro	Gln	Ile	Ile	Ser	Phe	Phe	Leu	Ala	Leu	Thr	Ser	Thr	
				185				190							195		
60	GCG	TTG	CTC	TTC	CTG	CTG	TTC	TTC	CTC	ACG	CTC	CGT	TTC	TCT	GTT	GTT	679
	Ala	Leu	Leu	Phe	Leu	Leu	Phe	Phe	Leu	Thr	Leu	Arg	Phe	Ser	Val	Val	
				200			205						210				
65	AAA	CCG	GGC	AGA	AAG	AAA	CTC	CTG	TAT	ATA	TTC	AAA	CAA	CCA	TTT	ATG	727
	Lys	Arg	Gly	Arg	Lys	Lys	Leu	Leu	Tyr	Ile	Phe	Lys	Gln	Pro	Phe	Met	
				215			220					225					
70	AGA	CCA	GTA	CAA	ACT	ACT	CAA	GAG	GAA	GAT	GGC	TGT	AGC	TGC	CGA	TTT	775
	Arg	Pro	Val	Gln	Thr	Thr	Gln	Glu	Glu	Asp	Gly	Cys	Ser	Cys	Arg	Phe	
						235					240				245		
75	CCA	GAA	GAA	GAA	GAA	GGA	GGA	TGT	GAA	CTG	TGAAATGGAA	GTCAATAGGG					825
	Pro	Glu	Glu	Glu	Glu	Gly	Gly	Cys	Glu	Leu							
					250					255							
80	CTGTTGGGAC	TTT															838

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 255 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

10 Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu
 1 5 10 15
 Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro
 20 25 30
 15 Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys
 35 40 45
 20 Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile
 50 55 60
 Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser
 65 70 75 80
 25 Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly
 85 90 95
 Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu
 100 105 110
 30 Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln
 115 120 125
 35 Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys
 130 135 140
 Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro
 145 150 155 160
 40 Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala
 165 170 175
 Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe Phe Leu
 180 185 190
 45 Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe Leu Thr Leu
 195 200 205
 50 Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
 210 215 220
 Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
 225 230 235 240
 55 Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
 245 250 255

(2) INFORMATION FOR SEQ ID NO:9:

60

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

65

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PCR Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

10 AATAAGCTTT GCTAGTATCA TACCT

25

(2) INFORMATION FOR SEQ ID NO:10:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PCR Primer"

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TTAAGATCTC TGCGGAGAGT GTCCTGGCTC

30



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: (301) 231-5520 Telex: 898-055 ATCC NORTH • FAX: 301-770-2587

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Indiana University Foundation
Attn: Byoung Se Kwon
Indiana University School of Medicine
Department of Microbiology & Immunology
635 Barnhill Drive, MS-255
Indianapolis, IN 46202-5120

Deposited on Behalf of: Indiana University Foundation

Identification Reference by Depositor:

ATCC Designation

Hybridoma that produces 4B4-1 mAb

HB-11860

The deposit was accompanied by: ☐ a scientific description ☐ a proposed taxonomic description
indicated above.

The deposit was received March 10, 1995 by this International Depository Authority and has been
accepted.

AT YOUR REQUEST:

☒ We will not inform you of requests for the strain.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right
to receive, or if a U.S. Patent is issued citing the strain and ATCC is instructed by the United States
Patent & Trademark Office or the depositor to release said strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your
responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years after the date of deposit, and for a period
of at least five years after the most recent request for a sample. The United States and many other
countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested March 15, 1995. On that date, the culture was
viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:


Annette L. Bade, Director, Patent Depository

Date: March 17, 1995


✓cc: Christopher A. Michaels

What is claimed is:

1. A monoclonal antibody against H4-1BB which preferentially binds to at least a portion of receptor protein H4-1BB.
- 5 2. A hybridoma capable of producing a monoclonal antibody of claim 1.
3. A method of using the monoclonal antibody of claim 1 to enhance T-cell proliferation comprising the step of treating T-cells that have expressed receptor protein H4-1BB with said monoclonal antibody.
- 10 4. The method of claim 3 further comprising the step of conducting said treatment in the presence of co-stimulatory molecule.
- 15 5. A method of using the monoclonal antibody of claim 1 to enhance T-cell activation comprising the step of treating T-cells that have expressed receptor protein H4-1BB with said monoclonal antibody.
6. The method of claim 5 further comprising the step of conducting said treatment in the presence of co-stimulatory molecule.
- 20 7. The method of using the monoclonal antibody of claim 1 to inhibit the interaction of H4-1BB and its ligand.


8. The method of using the monoclonal antibody of claim 1 to aid in killing cancer cells by using said monoclonal antibody to activate T-cells against said cancer cells.
- 5 9. The method of using the monoclonal antibody of claim 1 to treat autoimmune diseases by using the monoclonal antibody to inhibit the interaction of H4-1BB and its ligand.
- 10 10. The method of using the monoclonal antibody of claim 1 to block a patient's immune response during organ transplantation by using the monoclonal antibody to inhibit the interaction of H4-1BB and its ligand.
- 15 11. An antibody that is immuno reactive with a purified human 4-1BB polypeptide comprising the N-terminal amino acid sequence Leu-Gln-Asp-Pro-Cys-Ser-Asn-Cys-Pro-Ala-Gly-Thr.
12. An antibody of claim 11, wherein said antibody is a monoclonal antibody.

1/3



COGNITIVE PHASE
early activation

Fig. 1a






PROLIFERATION
CLONAL EXPANSION
late activation

Fig. 1b




2/3

NORMAL T-CELL ACTIVATION PATHWAY

*Fig. 2a**Fig. 2b**Fig. 2c*

3/3

BLOCKING STEPS IN T-CELL ACTIVATION PATHWAY



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/03965**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07K 16/00; C12N 5/00; G01N 33/53; A61K 39/395

US CL : 530/387.9, 388.24; 435/7.24, 240.27; 424/145.1, 158.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.9, 388.24; 435/7.24, 240.27; 424/145.1, 158.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	ALDERSON, M.R. et al. Molecular and Biological characterization of Human 4-1BB and its ligand. Eur. J. Immunol.. 1994, 24(9), pages 2219-2227.	1-2, 11-12 ----- 3-10
X -- Y	SCHWARZ, H. et al. ILA, the Human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood, 15 Febuary 1995, Vol.85, N.4, pages 1043-1052.	1-2, 11-12 ----- 3-10

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
---	--	--

Date of the actual completion of the international search

23 JUNE 1996

Date of mailing of the international search report

02 AUG 1996

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 308-4242

Authorized officer

MINH TAM B. DAVIS

Telephone No. (703) 305-2008

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/03965

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

DIALOG, WPI, MPSRCH.REGISTRY. Search terms: sequences 2, 8, and the sequence cited in claim 11, antibody, nerve growth factor receptor, tumor necrosis factor, autoimmune disease treatment, cancer treatment, h4-1bb, ILA and lymphocyte activation.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claims 1-6 and claims 11-12 are drawn to : 1) an antibody or a monoclonal antibody against receptor protein H4-1BBB, 2) a hybridoma capable of producing said antibody to enhance T-cells proliferation and activation, and 3) a method of using said monoclonal antibody to enhance T-cell proliferation and activation.

Group II, claims 7,9-10 are drawn to a method of using said monoclonal antibody to treat autoimmune diseases and to block a patient's immune response during organ transplantation.

Group III, claim 8 is drawn to a method of using said monoclonal antibody to aid in killing cancer cells.

The inventions listed as Groups I, II and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of the Group I invention is an antibody or a monoclonal antibody against H4-1BBB, a hybridoma producing said antibody, and a first method of using said monoclonal antibody by treating T-cells with said antibody. The special technical feature of the Group II invention is a second method of using said monoclonal antibody which is to treat autoimmune diseases and to block a patient's immune response during organ transplantation. The special technical feature of the Group III invention is a third method of using said monoclonal antibody which is to aid in killing cancer cells. The techniques and reagents used for producing antibody, hybridoma and treating T-cells of the Group I do not pertain to those used for treating autoimmune diseases, blocking a patient's immune response and treating cancer, and vice-versa. The techniques and reagents used for treating cancer are different from those used for treating autoimmune diseases and for blocking immune response during organ transplantation. Therefore unity of invention is lacking. Treating autoimmune diseases and blocking a patient's immune response during organ transplantation are grouped together in group II because there is no extra burden for the examiner to search both treatments.